
Attachment 3 - ClinicalTrials.gov Registration Data Entry Screen Shots



Parent Organizations, if any:	
* Official Representative:	.41
* Phone:	Please enter a valid phone number, including area code.
* Email:	
Organization URL (optional):	
Funding Organization:	
	The PRS Administrator is the person authorized by the sponsor to update the the point of contact for ClinicalTrials.gov staff.
* Administrator Name:	
Affiliation (if not the sponsor):	
* Administrator Phone:	Please enter a valid phone number, including area code.
* Administrator Email:	
review board, or an ethics committe * Regulatory Authority:	
* Regulatory Authority Address:	
To the best of my knowledge, the al Questions about this form and the F	bove information is true and correct. PRS may be sent to register@ClinicalTrials.gov.
* Required	Submit Application Reset
	This page last reviewed in December 2014
	This page last reviewed in December 2014 TO TOP
For Patients and	^ ТО ТОР
	^ ТО ТОР

ClinicalTrials.gov PRS	
Protocol Registration and Results Sys	ten

Login	
Welcome to the ClinicalTrials.gov Protocol Registration and Results System (PRS).	OME NO: 0925-0580 EXPIRATION DATE: 09/31/2015 Burden Statement
Organization: One-word organization name assigned by PRS (sent via email	when account was created)
Username:	,
Password: Forgot password	
Login See Submit Studies on ClinicalTrials.gov for information on how to apply for an account, how to register your standard email to ClinicalTrials.gov PRS Administration	tudy, and how to submit results.

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services

OMB NO: 0925-0586

EXPIRATION DATE: 08/31/2015

Burden Statement

Public reporting burden for this collection of information is estimated to average 7.0 hours per response for initial registration, 2.0 hours for each of 8 updates to the registration information during the course of the trial, 25.0 hours per response for initial results submission, 8.0 hours for two substantive updates to the results information. These estimates include the time for reviewing instructions, searching existing data sources, gathering the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0586). Do not return the completed form to this address



Contact ClinicalTrials.gov PRS

Create New Record

To avoid duplicate or invalid registration of your study, check the following before proceeding with registration:

- FDAAA 801 studies may only be registered by the Responsible Party. If this is an applicable clinical trial as defined by the US Food and Drug Administration Amendments Act (FDAAA), Title VIII, Section 801, ensure that your organization is the Responsible Party as defined by the law before registering the study.
- 2. IND/IDE studies may only be registered by the IND/IDE holder. If the study is subject to US Food and Drug Administration regulations, under an Investigational New Drug (IND) Application or Investigational Device Exemption (IDE), ensure that your organization is the IND/IDE holder before registering the study.
- For NIH-funded studies, coordinate with the relevant Institute or Center. If this is a US National Institutes of Health (NIH) funded study, registration should be coordinated with the sponsoring NIH Institute or Center to avoid duplicate registration.
- 4. Multi-site studies are NOT registered by individual sites. If this is a multi-site study it must be registered only once, by the sponsor (primary organization that oversees implementation of study and is responsible for data analysis) or its designated principal investigator (PI).
- Coordinate with all collaborators before registering. If the study has multiple collaborators, contact the other organizations to
 confirm that the study has not already been registered and to notify them that your organization, as sponsor or its designated
 PI, is registering the study.
- 6. Refer to the ClinicalTrials.gov Review of Protocol Submissions document for a description of items evaluated by ClinicalTrials.gov after protocol information is submitted.



NLM ID: 12345678910A Sample Clinical Trial 2 [NCT ID not yet assigned]

Edit Study Identification

Help Definitions * ‡ Organization's Unique Protocol ID: 12345678910 * ‡ Brief Title: Somela Clinical Title!

* ‡ Brief Title:	Sample Clinical Trial
	• NOTE: A title this short is probably not sufficiently descriptive.
Acronym:	If specified, will be included at end of Brief Title in parentheses.
Official Title:	
	NOTE: Official Title is required by the WHO and ICMJE.
‡ Secondary IDs: (if any)	+ Add Secondary ID
Continue Quit *	Required by ClinicalTrials.gov

* Required by ClinicalTrials.gov

‡ = FDAAA Required to comply with US FDA Amendments Act

(‡) = (FDAAA) May be required to comply with US FDA Amendments Act

Home > Record Summary > Protocol Section > Study Status NLM ID: 12345678910A Sample Clinical Trial 2 [NCT ID not yet assigned] Edit Study Status Help Definitions * 1 Record Verification Date: → Year: 2015 *

† Overall Recruitment Status: --Select--Tip: Before selecting Suspended, Terminated or Withdrawn see the Overall Recruitment Status definition. ‡ Study Start Date: --Select- ▼ Year: * ‡ Primary Completion Date: --Select- ▼ Year: Type: --Select--Final data collection date for primary outcome measure. Study Completion Date: --Select-- ▼ Year: Type: --Select-- ▼ Final data collection date for study. Continue * Required by ClinicalTrials.gov Back Quit 1 = FDAAA Required to comply with US FDA Amendments Act (‡) = (FDAAA) May be required to comply with US FDA Amendments Act Home > Record Summary > Protocol Section > Sponsor/Collaborators ID: 12345678910A NLM Sample Clinical Trial 2 [NCT ID not yet assigned] Edit Sponsor/Collaborators Help Definitions * ‡ Responsible Party: Sponsor Select Sponsor unless the Investigator has been designated as Responsible Party per FDAAA. * ‡ Sponsor: National Library of Medicine Primary organization conducting study and associated data analysis (not necessarily a funding source). Collaborators: × Delete + Add Collaborator Organization(s) providing support: funding, design, implementation, data analysis or reporting. Enter only the organization name. * Required by ClinicalTrials.gov Continue Back Quit 1 = FDAAA Required to comply with US FDA Amendments Act (‡) = (FDAAA) May be required to comply with US FDA Amendments Act

Home > Record Summary > Protocol Solution ID: 12345678910A	Sample Clinical Trial 2	MOTID activities
ID. 123456789TUA	Sample Clinical Trial 2 Edit Oversight	[NCT ID not yet assigned
	Help DefinitionsSelect- ▼	
(‡) FDA Regulated Intervention?	dministration (FDA) regulations?	
* (*) IND/IDE Destes alo		, , , ,
* (‡) IND/IDE Protocol? (Not public)	—Select- ▼ FDA Investigational New Drug (IND) Application or Investigational Device Exempton	otion (IDE)?
* Board Approval	Status:Select ▼	
* Board Name		
* Board Affiliation		
* Board Contact	Business Phone: Extension:	
(Not public)	Business Email:	
	Business Address:	
Data Monitoring Committee?	Select- ▼	
* Oversight Authorities		v Delete (
		× Delete
	+ Add Oversight Authority List of oversight authorities Format (in English) as Country: Organization Name	
	Examples: United States: Food and Drug Administration	
	Germany: Federal Institute for Drugs and Medicinal Devices	
	* Required by ClinicalTrials.gov	
Continue Back Quit	‡ = FDAAA Required to comply with US FDA Amendments Act	
	(‡) = (FDAAA) May be required to comply with US FDA Amendments Act	
	U.S. National Library of Medicine U.S. National Institutes of Health U.S. Departs	ment of Health & Human Services
· · · · · · · · · · · · · · · · · · ·		INCT ID not vet assigned
· · · · · · · · · · · · · · · · · · ·	Sample Clinical Trial 2	[NCT ID not yet assigned
NLM ID: 12345678910A	Sample Clinical Trial 2 Edit Study Description	[NCT ID not yet assigned
NLM ID: 12345678910A	Sample Clinical Trial 2	[NCT ID not yet assigned
NLM ID: 12345678910A	Sample Clinical Trial 2 Edit Study Description	[NCT ID not yet assigned
NLM ID: 12345678910A	Sample Clinical Trial 2 Edit Study Description	[NCT ID not yet assigned
NLM ID: 12345678910A	Sample Clinical Trial 2 Edit Study Description	[NCT ID not yet assigned
NLM ID: 12345678910A	Sample Clinical Trial 2 Edit Study Description	[NCT ID not yet assigned
NLM ID: 12345678910A	Sample Clinical Trial 2 Edit Study Description	[NCT ID not yet assigned
NLM ID: 12345678910A	Sample Clinical Trial 2 Edit Study Description	[NCT ID not yet assigned
ID: 12345678910A	Sample Clinical Trial 2 Edit Study Description Definitions	
* ‡ Brief Summary:	Sample Clinical Trial 2 Edit Study Description Definitions	[NCT ID not yet assigned
NLM ID: 12345678910A	Sample Clinical Trial 2 Edit Study Description Definitions	
* ‡ Brief Summary:	Sample Clinical Trial 2 Edit Study Description Definitions	
* ‡ Brief Summary:	Sample Clinical Trial 2 Edit Study Description Definitions	
* ‡ Brief Summary:	Sample Clinical Trial 2 Edit Study Description Definitions	
* ‡ Brief Summary:	Sample Clinical Trial 2 Edit Study Description Definitions	
* ‡ Brief Summary:	Sample Clinical Trial 2 Edit Study Description Definitions	
* ‡ Brief Summary:	Sample Clinical Trial 2 Edit Study Description Definitions	
* ‡ Brief Summary:	Sample Clinical Trial 2 Edit Study Description Definitions	
* ‡ Brief Summary:	Sample Clinical Trial 2 Edit Study Description Definitions	
* ‡ Brief Summary:	Sample Clinical Trial 2 Edit Study Description Definitions	
* ‡ Brief Summary:	Sample Clinical Trial 2 Edit Study Description Definitions	
* ‡ Brief Summary:	Sample Clinical Trial 2 Edit Study Description Definitions	cial Characters
* ‡ Brief Summary:	Sample Clinical Trial 2 Edit Study Description Definitions Special Study Description Adaptive Study Description Special Study Description	cial Characters
* ‡ Brief Summary:	Sample Clinical Trial 2 Edit Study Description Definitions Special Study Description Adjusted by Special Study Description *Required by ClinicalTrials.gov	cial Characters
NLM ID: 12345678910A Help * I Brief Summary: Detailed Description:	Sample Clinical Trial 2 Edit Study Description Definitions Special Study Description Special Study	
NLM ID: 12345678910A Help * ‡ Brief Summary: Detailed Description:	Sample Clinical Trial 2 Edit Study Description Definitions Special Study Description Adjusted by Special Study Description *Required by ClinicalTrials.gov	cial Characters

Home > Record Summary >			
NLM ID: 123456789	910A	Sample Clinical Trial 2 Edit Conditions	[NCT ID not yet assigned
		Help Definitions	
* ‡ Conditions or Focus of Study:		× Delete	
		Search MeSH, the National Library of Medicine's Medical Subject Headings, for valid condition terms. If there are no conditions under study, enter brief description of focus of study instead.	
		+ Add Condition	
	Vousuordo:		
	Keywords:	+ Add Keyword	
Continue Back	Quit	* Required by ClinicalTrials.gov	
		‡ = FDAAA Required to comply with US FDA Amendments Act	
		(‡) = (FDAAA) May be required to comply with US FDA Amendments Act	
		U.S. National Library of Medicine U.S. National Institutes of Health U.S. Department of Health & Human Services	
Home > Record Summary > NLM ID: 12345678		<u> </u>	BICT IDtt
ID. 12345076	310A	Sample Clinical Trial 2 Edit Interventional Study Design	[NCT ID not yet assigned
	Help De	finitions	
Study Type:			
‡ Primary Purpose:	Select		
* ‡ Study Phase:			
‡ Study Filase.		A" for trials that do not involve drug or biologic products.	
(‡) Intervention Model:	Select	•	
(‡) Number of Arms:			
(‡) Masking:	Select	Marked Dalas, E.C. biant	
(‡) Musking.	Select-	Masked Roles: □ Subject □ Caregiver	
		☐ Investigator ☐ Outcomes Assessor	
(‡) Allocation:		<u> </u>	
Study Classification:	Select	· · · · · · · · · · · · · · · · · · ·	
‡ Enrollment:	Number o	f Subjects: Type:Select- •	
Continue Back	Quit	* Required by ClinicalTrials.gov	
		‡ = FDAAA Required to comply with US FDA Amendments Act	
		(‡) = (FDAAA) May be required to comply with US FDA Amendments Act	

Home > Record Summary > Protocol Section > Arms and Interventions > Arms NLM ID: 12345678910A Sample Clinical Trial 2 [NCT ID not yet assigned] **Edit Arms** Help Definitions Arms: * (‡) Arm Label: Arm 1 Brief, descriptive label to be used as row or column heading in tables. * (‡) Arm Type: Experimental (‡) Arm Description: Describe the intervention(s) to be administered. For drugs use generic name and include dosage form, dosage, frequency and duration. × Delete Arm + Add Arm * Required by ClinicalTrials.gov Save Cancel ‡ = FDAAA Required to comply with US FDA Amendments Act (‡) = (FDAAA) May be required to comply with US FDA Amendments Act U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services Home > Record Summary > Protocol Section > Arms and Interventions > Interventions NLM ID: 12345678910A Sample Clinical Trial 2 [NCT ID not yet assigned] **Edit Interventions** Help Definitions Arms: Experimental: Arm 1 Active Comparator: Atm 2 Interventions: * ‡ Intervention Type: Drug * ‡ Intervention Name: Drug XYZ For a drug, use generic name if established.
Use the same name as in the associated Arm/Group Description(s) Other Names: × Delete + Add Other Name Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site. (‡) Intervention Description: Do not repeat information already included in arm/group descriptions. × Delete Intervention + Add Intervention * Required by ClinicalTrials.gov Save Cancel 1 = FDAAA Required to comply with US FDA Amendments Act (‡) = (FDAAA) May be required to comply with US FDA Amendments Act

1 June 2015 Attachment 3

Home > Record Summary > Protocol Section > Arms and Interventions > Cross-Reference NLM ID: 12345678910A Sample Clinical Trial 2 [NCT ID not yet assigned] Edit Arm/Intervention Cross-Reference Help Definitions * (‡) Cross-Reference: Interventions Arms Drug: Drug XYZ Drug: Drug ABC Experimental: Arm 1 Active Comparator: Atm 2 Check boxes for Interventions associated with each Arm in the study. * Required by ClinicalTrials.gov Save Cancel \ddagger = FDAAA Required to comply with US FDA Amendments Act (‡) = (FDAAA) May be required to comply with US FDA Amendments Act U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services Home > Record Summary > Protocol Section > Outcome Measures ID: 12345678910A Sample Clinical Trial 2 [NCT ID not yet assigned] **Edit Outcome Measures** Help Definitions * ‡ Primary Outcome Measure: Outcome 1 * Title: * Time Frame: Description: (‡) Safety Issue? --Select- ▼ × Delete Outcome + Add Primary Outcome ‡ Secondary Outcome Measures:

+ Add Secondary Outcome

Other Pre-specified Outcomes:


+ Add Other Outcome

Continue

Back Quit * Required by ClinicalTrials.gov

‡ = FDAAA Required to comply with US FDA Amendments Act

(1) = (FDAAA) May be required to comply with US FDA Amendments Act



Home > Rec	ord Summary > Protocol Sectio	n > References	
NLM	ID: 12345678910A	Sample Clinical Trial 2	[NCT ID not yet assigned]
		Edit References	
	Help Definitions		
Citations:	PubMed ID:	Lookup Use the PubMed Citation Matcher to search for citations based on journal name, date, author(s), title and other criteria.	
	Citation:		
	Results Reference? -s	elect- ▼	
		Enter Citation Text	
	+ Add Citation		
Links:	URL: http://		
	Description:		
		× Delete Link	
	+ Add Link		
Continue	Back Quit	*Required by ClinicalTrials.gov ‡ = FDAAA Required to comply with US FDA Amendments Act	
		(‡) = (FDAAA) May be required to comply with US FDA Amendments Act	